SAWAI GROUP HOLDINGS Co., Ltd.
sawaigroup.holdingsNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2021 20-F, filed Jun 28, 2021. Its latest SEC filing is a 15F-15D from Dec 22, 2021.
20-F for FY2021, filed Jun 28, 2021
The sections below describe the company as of the FY2021 annual report.
What Did They Do?
Manufactures and sells generic prescription medicines and USL-branded medicines to pharmaceutical distributors and wholesalers, retailers, and medical institutions in Japan and the United States.
20-F for FY2021, filed Jun 28, 2021The Company manufactures and sells various prescription medications primarily in Japan and the United States. Its main products are generic…View ↗
In the United States, the Company also manufactures and sells drugs that have the same active pharmaceutical ingredients as…View ↗
Japan Business segment. The Japan Business segment is the Company’s primary operating business segment by revenue. The Company manufactures…View ↗
U.S. Business segment. The Company expanded its business to the U.S. market through the acquisition of USL by Sawai Pharmaceutical in 2017.…View ↗
Who Were Their Customers?
In Japan, it sells through distributors, retail stores and other pharmaceutical manufacturers, and directly to medical institutions; in the United States, it sells to wholesalers.
20-F for FY2021, filed Jun 28, 2021
Loading...
